Founded in 2024, Korsana Biosciences is focused on creating best-in-class biologics for neurodegenerative disorders using its proprietary Therapeutic Targeting (THETA™) platform, which employs transferrin-receptor (TfR1) engineering to enhance drug delivery across the blood-brain barrier. Its lead candidate, KRSA-028, is a next-generation shuttled monoclonal antibody that selectively targets amyloid beta plaques and is designed for subcutaneous administration, aiming to improve efficacy, safety, and patient convenience over first-generation Alzheimer’s therapies. Preclinical data suggest superior plaque clearance with reduced amyloid-related imaging abnormalities (ARIA) and hematologic adverse events. The company is also advancing a pipeline of additional THETA-enabled programs for other undisclosed neurodegenerative diseases with high unmet need. Korsana’s cash runway extends into 2028, funding clinical milestones that include healthy-volunteer pharmacokinetic and CNS-penetration data by mid-2027 and initial proof-of-concept amyloid-plaque-clearance data in Alzheimer’s patients by year-end 2027. The company operates from Waltham, Massachusetts, and is led by CEO Jonathan Violin, Ph.D.

Total raised

$150M

Funding rounds

1

Latest round

Series A

Latest activity

Feb 2026